Context Therapeutics Inc. (CNTX): R&D Expense
$31.86M
Year ended 2025-12-31
$40.11M
Trailing 12 months to 2026-06-30
+65.0%
3-year compound annual growth
+81.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $31.86M | +40.3% | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | $22.70M | +27.7% | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | $17.78M | +150.8% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $7.09M | +86.4% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $3.81M | +131.8% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $1.64M | n/a | 2022-03-23, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | $31.86M | +40.3% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $38.47M | -60.2% |
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $44.83M | -20.6% |
| Grace Therapeutics, Inc. (GRCE) | 2026-03-31 | $2.40M | -74.7% |
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $33.72M | +73.9% |
| Aldeyra Therapeutics, Inc. (ALDX) | 2025-12-31 | $25.66M | -46.8% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $54.21M | -28.3% |
| Rallybio Corp (RLYB) | 2025-12-31 | $19.60M | -52.8% |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | $48.26M | +10.2% |
Compare CNTX, SPRO, HOWL, GRCE side by side · Screen every company in Pharmaceutical Preparations ↗